Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
âAs of today, and based on early clinical benefits, four cancer types (colorectal, ovarian, cutaneous melanoma and uveal melanoma) have been selected as the candidate expansion cancer types for Part III.â
Part II must be going well!
I donât know the rules on whether an RNS would have to be issued. He literally spent a few seconds on Haematokine as a new therapy in the company introduction (it was named on the slide too with the words âAOC3-dependent cell replicationâ). But the rest of the presentation was Clevegen then Traumakine as usual.
Does anyone know the rules?
Iâve just watched Markkuâs presentation.
Regarding Clevegen, he didnât present any new data (I guess that is still under review and would require RNS anyway) but he did show plans for future trials in combination with other drugs as well as continuing as a mono-therapy.
Nothing new on Traumakine but again reiterated that results from Solidarity could come at any time.
Potentially most interesting was that he also introduced Haematokine - a new treatment to rebuild Haematopoietic Stem Cells (aka blood stem cells) in patients who have lost them. First time that has been mentioned anywhere so Iâm guessing itâs the long promised âsecret weaponâ.
So now we have Clevegen, Traumakine and Haematokine.
Iâm still expecting an RNS update ahead of Weds. We know they have more Clevegen data and a manuscript has been in review for a while now.
Of course, they might not be ready with the update but I imagine they will have been doing all they can to sign it off in time. I doubt Markku would want to present six month old data if he can avoid it!
The 22m warrants were issued at the Feb fund raise. Investors in that raise received one warrant for every two shares they bought at that time.
They can exercise the warrants (i.e purchase these shares) for ÂŁ1 each at any point up to the 5th anniversary if the raise.
The scale of rise on Blautix news will depend on three things IMO:
1) How good the P2 results are... we know from preliminary analysis they are ânot trivialâ but I think we are all expecting (or at least hoping for) strong evidence of efficacy.
2) News on nature and timing of pivotal trial.
3) Commercialisation - we know 4D arenât planning on going it alone on this one, so true value from good results will only be clear once the financials of any partnership are known.
We are all expecting news on 1) shortly. We donât know the degree to which 4D have progressed 2) and 3) since April but if they have these lined up too, then the rise could be spectacular.
We must be due an update (16th is exactly 3 months since the R&D day and associated updates). We also know thereâs a Clevegen manuscript in review so surely theyâll be trying their best to release it in time for the Conference.
So Iâm expecting an RNS in the next 7 days. And based on Maiyaâs tweet, it should be good news!
Who was it that said it feels like waiting for the lottery draw with the winning ticket in your hand? Very apt right now!
@Diversified. 4D and FARN are my two big biotech positions and they are quite interesting to compare as you say.
Today's results from 4Dâs cancer programme are in many ways the equivalent of FARNâs Clevegen results in March. Both programmes are the what the respective management teams are most excited about in terms of long term value drivers but I expect FARNâs value from Clevegen to come through much faster due to the Matins trial design and expanded cohort enrolment to date.
FARNâs value pre-Covid was almost exclusively due to Clevegen. This yearâs rise to date has been from a mixture of the Matins results in March, and subsequently the Covid acceleration / re-birth of Traumakine.
Both can (and should) add significant shareholder value in the next six months but, yes, I fully expect Clevegen to dwarf Traumakine in the long run (5 years or so out).
Hmmm. I'm a huge believer in Faron but the website is still very amateurish.
Not that it matters, yet. They are a small team and I'd far rather they focused on the science. We're so far under the radar i expect the only people visiting the site are us investors!
Interesting market projection and positive as far as it goes.
But it clearly hasn't taken into account disruptive events. If our combination with Keytruda works (and the 4D team seem very confident) that prediction will look silly. I don't think the analysts get it (yet)!
@MaryMoo, I have met Markku twice in the last 18 months and in my opinion he is 100% genuine.
Also imo they view Clevegen as a potential blockbuster (think Keytruda scale) so they would never risk their credibility by gaming the market for Covid/Traumakine.
I would have thought that a combination treatment wouldn't necessarily need to be administered at the same time.
They need to get the timing of the interventions right and i believe we will end up with a SoC involving multiple drugs at different stages of disease progression.
Ah, yes, I do remember this. But it looks like Priaxon went out of business in c. 2014.
Of course, we did acquire rights to an AOC3 antagonist platform (RNS 2nd March), but I'm not sure if there's a link to anything coming from this Priaxon collaboration or the secret weapon. According to the RNS this platform was developed in Faron's scientific network and Sirpa is listed as a related party so it doesn't sound like they are related unless she continued the research after Priaxon stopped trading.
I can't recall one.
But it does remind me that we have ongoing arbitration with Rentschler over their termination of the original Traumakine manufacturing agreement. I can only imagine the lawyers are wrangling over damages - must at least cover the Business Finland loan, costs to scale manufacturing, plus any loss of revenue due to not being able to supply to market demand in the interim. If WHO come out on our side soon this could be quite an interesting sum.
Not really - we've known it exists for a while. We refer to it as the 'secret weapon'.
The only thing I have seen that may give a clue is the reference to a 2018 onwards 'ground breaking discovery of the functionality of lymph node lymphatics leading to several targets to prevent cancer metastasis' which was on the first slide of Juho's conference presentation in Feb. But I'm no medic so it could easily refer to another part of the Clevegen world!
Mantovani spoke at the June R&D day didn't he? The one where they had to delete something a guest speaker said as it was confidential? Maybe it was something to do with this paper? Seems like they all know each other.
Anyway, they will have a lot of data from the expanded Matins cohorts now as it's open label. If there was any bad news i expect they would have had to release an RNS by now. So I'm assuming that it is all progressing as they expected, i.e. One ring to rule them all!